peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Directed new share issue by Hansa Medical AB (publ) completed

25 Jan 2012, 08:50
Regulatory information

On January 9 2012 a Hansa Medical AB (publ) Extraordinary Meeting resolved to follow the proposal of the Board of Directors of Hansa Medical to carry out a directed share issue to NXT2B, the privately owned venture capital firm of Bengt Ågerup. The share issue comprising 5,000,001 shares at the share price SEK 5.50 is now completed and the share issue has provided SEK 27.5 million to Hansa Medical AB (publ). The share issue has increased the company’s share capital by SEK 25,000,005 and today amounts SEK 92,605,725. The total number of outstanding shares is 18,521,145 after the share emission and NXT2B holds 27.0 percent of the outstanding shares.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, EndoS and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium Nordic AB is Certified Adviser to Hansa Medical.